Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2022.1030094
Abstract: Osteosarcoma is a high-grade sarcoma characterized by osteoid formation, nearly universal expression of IGF1R and with a subset expressing HER-2. These qualities provide opportunities for the use of the alpha particle-emitting isotopes to provide targeted… read more here.
Keywords: thorium 227; particle; targeted alpha; alpha particle ... See more keywords
Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2022.1033303
Abstract: Targeted thorium-227 conjugates comprise the combination of a monoclonal antibody with specificity for a tumor cell antigen and a 3,2-HOPO chelator enabling complexation of thorium-227 (Th-227). The radiolabeled conjugate functions as an effective delivery system… read more here.
Keywords: tumor growth; tumor; inhibition; thorium 227 ... See more keywords
Targeted thorium-227 conjugates as treatment options in oncology
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2022.1071086
Abstract: Targeted alpha therapy (TAT) is a promising approach for addressing unmet needs in oncology. Inherent properties make α-emitting radionuclides well suited to cancer therapy, including high linear energy transfer (LET), penetration range of 2–10 cell… read more here.
Keywords: oncology; thorium; thorium 227; targeted thorium ... See more keywords